Literature DB >> 20234379

The asparaginyl endopeptidase legumain after experimental stroke.

Taku Ishizaki1, Agnes Erickson, Enida Kuric, Mehrdad Shamloo, Ikuko Hara-Nishimura, Ana Rita Lourenço Inácio, Tadeusz Wieloch, Karsten Ruscher.   

Abstract

Various proteases in the brain contribute to ischemic brain injury. We investigated the involvement of the asparaginyl endopeptidase legumain after experimental stroke. On the basis of gene array studies and in situ hybridizations, we observed an increase of legumain expression in the peri-infarct area of rats after transient occlusion of the middle cerebral artery (MCAO) for 120 mins with a maximum expression at 24 and 48 h. Immunohistochemical analyses revealed the expression of legumain in Iba1(+) microglial cells and glial fibrillary acidic protein-positive astrocytes of the peri-infarct area in mice after MCAO. Post-stroke recovery was also studied in aged legumain-deficient mice (45 to 58 weeks old). Legumain-deficient mice did not show any differences in physiologic parameters compared with respective littermates before, during MCAO (45 mins), and the subsequent recovery period of 8 days. Moreover, legumain deficiency had no effect on mortality, infarct volume, and the neurologic deficit determined by the rotating pole test, a standardized grip strength test, and the pole test. However, a reduced number of invading CD74(+) cells in the ischemic hemisphere indicates an involvement in post-stroke inflammation. We conclude that legumain is not essential for the functional deficit after MCAO but may be involved in mechanisms of immune cell invasion.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20234379      PMCID: PMC3023405          DOI: 10.1038/jcbfm.2010.39

Source DB:  PubMed          Journal:  J Cereb Blood Flow Metab        ISSN: 0271-678X            Impact factor:   6.200


  39 in total

Review 1.  Cytokines: powerful regulators of glial cell activation.

Authors:  Gareth R John; Sunhee C Lee; Celia F Brosnan
Journal:  Neuroscientist       Date:  2003-02       Impact factor: 7.519

2.  Effects of normothermic versus mild hyperthermic forebrain ischemia in rats.

Authors:  W D Dietrich; R Busto; I Valdes; Y Loor
Journal:  Stroke       Date:  1990-09       Impact factor: 7.914

Review 3.  Non-pharmacologic (physiologic) neuroprotection in the treatment of brain ischemia.

Authors:  R N Auer
Journal:  Ann N Y Acad Sci       Date:  2001-06       Impact factor: 5.691

4.  Fibronectin matrix turnover occurs through a caveolin-1-dependent process.

Authors:  Jane Sottile; Jennifer Chandler
Journal:  Mol Biol Cell       Date:  2004-11-24       Impact factor: 4.138

5.  Neuronal activity-dependent increase of net matrix metalloproteinase activity is associated with MMP-9 neurotoxicity after kainate.

Authors:  Jérôme Jourquin; Evelyne Tremblay; Nadège Décanis; Gérard Charton; Stephen Hanessian; Anne-Marie Chollet; Thierry Le Diguardher; Michel Khrestchatisky; Santiago Rivera
Journal:  Eur J Neurosci       Date:  2003-09       Impact factor: 3.386

6.  Multistep autoactivation of asparaginyl endopeptidase in vitro and in vivo.

Authors:  Dongtao Ni Li; Stephen P Matthews; Antony N Antoniou; Daniela Mazzeo; Colin Watts
Journal:  J Biol Chem       Date:  2003-07-14       Impact factor: 5.157

Review 7.  Cellular and molecular events underlying the dysregulated response of the aged brain to stroke: a mini-review.

Authors:  Eugen Bogdan Petcu; Veronica Sfredel; Dieter Platt; James G Herndon; Christof Kessler; Aurel Popa-Wagner
Journal:  Gerontology       Date:  2007-12-21       Impact factor: 5.140

8.  Focal cerebral ischemia induces active proteases that degrade microvascular matrix.

Authors:  Shunichi Fukuda; Catherine A Fini; Takuma Mabuchi; James A Koziol; Leonard L Eggleston; Gregory J del Zoppo
Journal:  Stroke       Date:  2004-03-04       Impact factor: 7.914

9.  Apolipoprotein D is elevated in oligodendrocytes in the peri-infarct region after experimental stroke: influence of enriched environment.

Authors:  Mattias Rickhag; Tomas Deierborg; Shutish Patel; Karsten Ruscher; Tadeusz Wieloch
Journal:  J Cereb Blood Flow Metab       Date:  2007-09-12       Impact factor: 6.200

10.  Expression of the cysteine protease legumain in vascular lesions and functional implications in atherogenesis.

Authors:  Valerie Clerin; Heather H Shih; Nanhua Deng; Gustave Hebert; Christine Resmini; Kathleen M Shields; Jeffrey L Feldman; Aaron Winkler; Leo Albert; Vasu Maganti; Anthony Wong; Janet E Paulsen; James C Keith; George P Vlasuk; Debra D Pittman
Journal:  Atherosclerosis       Date:  2008-02-21       Impact factor: 5.162

View more
  12 in total

1.  Behavioral abnormalities and circuit defects in the basal ganglia of a mouse model of 16p11.2 deletion syndrome.

Authors:  Mu Yang; Rong Mao; Georgia Panagiotakos; Thomas Portmann; Jacob Ellegood; Gul Dolen; Patrick L Bader; Brad A Grueter; Carleton Goold; Elaine Fisher; Katherine Clifford; Pavitra Rengarajan; David Kalikhman; Darren Loureiro; Nay L Saw; Zhou Zhengqui; Michael A Miller; Jason P Lerch; Mark Henkelman; Mehrdad Shamloo; Robert C Malenka; Jacqueline N Crawley; Ricardo E Dolmetsch
Journal:  Cell Rep       Date:  2014-05-01       Impact factor: 9.423

2.  Legumain Knockout Protects Against Aβ1-42-Induced AD-like Cognitive Deficits and Synaptic Plasticity Dysfunction Via Inhibiting Neuroinflammation Without Cleaving APP.

Authors:  Runwen Chen; Qiyue Zhang; Yuxing Yan; Yuying Zhang; Tao Zhang
Journal:  Mol Neurobiol       Date:  2020-11-21       Impact factor: 5.590

3.  Functional imaging of legumain in cancer using a new quenched activity-based probe.

Authors:  Laura E Edgington; Martijn Verdoes; Alberto Ortega; Nimali P Withana; Jiyoun Lee; Salahuddin Syed; Michael H Bachmann; Galia Blum; Matthew Bogyo
Journal:  J Am Chem Soc       Date:  2012-12-18       Impact factor: 15.419

Review 4.  Asparagine endopeptidase is an innovative therapeutic target for neurodegenerative diseases.

Authors:  Zhentao Zhang; Manling Xie; Keqiang Ye
Journal:  Expert Opin Ther Targets       Date:  2016-05-13       Impact factor: 6.902

5.  Activation of asparaginyl endopeptidase leads to Tau hyperphosphorylation in Alzheimer disease.

Authors:  Gustavo Basurto-Islas; Inge Grundke-Iqbal; Yunn Chyn Tung; Fei Liu; Khalid Iqbal
Journal:  J Biol Chem       Date:  2013-05-02       Impact factor: 5.157

6.  δ-Secretase-cleaved Tau stimulates Aβ production via upregulating STAT1-BACE1 signaling in Alzheimer's disease.

Authors:  Zhentao Zhang; Xiao-Guang Li; Zhi-Hao Wang; Mingke Song; Shan Ping Yu; Seong Su Kang; Xia Liu; Zhaohui Zhang; Manling Xie; Gong-Ping Liu; Jian-Zhi Wang; Keqiang Ye
Journal:  Mol Psychiatry       Date:  2018-10-31       Impact factor: 15.992

7.  Legumain is activated in macrophages during pancreatitis.

Authors:  Laura E Edgington-Mitchell; Thomas Wartmann; Alicia K Fleming; Vasilena Gocheva; Wouter A van der Linden; Nimali P Withana; Martijn Verdoes; Luigi Aurelio; Daniel Edgington-Mitchell; TinaMarie Lieu; Belinda S Parker; Bim Graham; Thomas Reinheckel; John B Furness; Johanna A Joyce; Peter Storz; Walter Halangk; Matthew Bogyo; Nigel W Bunnett
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2016-08-11       Impact factor: 4.052

8.  Effects of the sigma-1 receptor agonist 1-(3,4-dimethoxyphenethyl)-4-(3-phenylpropyl)-piperazine dihydro-chloride on inflammation after stroke.

Authors:  Karsten Ruscher; Ana R Inácio; Kristian Valind; Arman Rowshan Ravan; Enida Kuric; Tadeusz Wieloch
Journal:  PLoS One       Date:  2012-09-18       Impact factor: 3.240

9.  Lack of macrophage migration inhibitory factor in mice does not affect hallmarks of the inflammatory/immune response during the first week after stroke.

Authors:  Ana R Inácio; Richard Bucala; Tomas Deierborg
Journal:  J Neuroinflammation       Date:  2011-06-29       Impact factor: 8.322

Review 10.  Heart failure and Alzheimer's disease.

Authors:  P Cermakova; M Eriksdotter; L H Lund; B Winblad; P Religa; D Religa
Journal:  J Intern Med       Date:  2014-08-01       Impact factor: 8.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.